These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
558 related articles for article (PubMed ID: 35545027)
21. Peritoneal Administration of a Subunit Vaccine Encapsulated in a Nanodelivery System Not Only Augments Systemic Responses against SARS-CoV-2 but Also Stimulates Responses in the Respiratory Tract. Jearanaiwitayakul T; Apichirapokey S; Chawengkirttikul R; Limthongkul J; Seesen M; Jakaew P; Trisiriwanich S; Sapsutthipas S; Sunintaboon P; Ubol S Viruses; 2021 Nov; 13(11):. PubMed ID: 34835008 [TBL] [Abstract][Full Text] [Related]
22. Promises and challenges of mucosal COVID-19 vaccines. Rathore APS; St John AL Vaccine; 2023 Jun; 41(27):4042-4049. PubMed ID: 37045682 [TBL] [Abstract][Full Text] [Related]
23. CCR2 Signaling Restricts SARS-CoV-2 Infection. Vanderheiden A; Thomas J; Soung AL; Davis-Gardner ME; Floyd K; Jin F; Cowan DA; Pellegrini K; Shi PY; Grakoui A; Klein RS; Bosinger SE; Kohlmeier JE; Menachery VD; Suthar MS mBio; 2021 Dec; 12(6):e0274921. PubMed ID: 34749524 [TBL] [Abstract][Full Text] [Related]
24. The immune response to SARS-CoV-2 and COVID-19 immunopathology - Current perspectives. Boechat JL; Chora I; Morais A; Delgado L Pulmonology; 2021; 27(5):423-437. PubMed ID: 33867315 [TBL] [Abstract][Full Text] [Related]
25. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection. Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J Front Immunol; 2022; 13():995235. PubMed ID: 36172368 [TBL] [Abstract][Full Text] [Related]
26. Efficacy of BCG Vaccination Against Respiratory Tract Infections in Older Adults During the Coronavirus Disease 2019 Pandemic. Moorlag SJCFM; Taks E; Ten Doesschate T; van der Vaart TW; Janssen AB; Müller L; Ostermann P; Dijkstra H; Lemmers H; Simonetti E; Mazur M; Schaal H; Ter Heine R; van de Veerdonk FL; Bleeker-Rovers CP; van Crevel R; Ten Oever J; de Jonge MI; Bonten MJ; van Werkhoven CH; Netea MG Clin Infect Dis; 2022 Aug; 75(1):e938-e946. PubMed ID: 35247264 [TBL] [Abstract][Full Text] [Related]
28. Breakthrough infection evokes the nasopharyngeal innate immune responses established by SARS-CoV-2-inactivated vaccine. He X; Cao Y; Lu Y; Qi F; Wang H; Liao X; Xu G; Yang B; Ma J; Li D; Tang X; Zhang Z Front Immunol; 2023; 14():1181121. PubMed ID: 37457721 [TBL] [Abstract][Full Text] [Related]
29. Mucosal vaccines for SARS-CoV-2: triumph of hope over experience. Pilapitiya D; Wheatley AK; Tan HX EBioMedicine; 2023 Jun; 92():104585. PubMed ID: 37146404 [TBL] [Abstract][Full Text] [Related]
31. Acquired immunity against SARS-CoV-2 infection and vaccination. Renia L; Ng LF EMBO Mol Med; 2023 Dec; 15(12):e16345. PubMed ID: 37966373 [TBL] [Abstract][Full Text] [Related]
32. Respiratory mucosal vaccination of peptide-poloxamine-DNA nanoparticles provides complete protection against lethal SARS-CoV-2 challenge. Sun S; Li E; Zhao G; Tang J; Zuo Q; Cai L; Xu C; Sui C; Ou Y; Liu C; Li H; Ding Y; Li C; Lu D; Zhang W; Luo P; Cheng P; Gao Y; Tu C; Pitard B; Rosenecker J; Wang B; Liu Y; Zou Q; Guan S Biomaterials; 2023 Jan; 292():121907. PubMed ID: 36436305 [TBL] [Abstract][Full Text] [Related]
33. Innate Immune Responses to Highly Pathogenic Coronaviruses and Other Significant Respiratory Viral Infections. Ahmed-Hassan H; Sisson B; Shukla RK; Wijewantha Y; Funderburg NT; Li Z; Hayes D; Demberg T; Liyanage NPM Front Immunol; 2020; 11():1979. PubMed ID: 32973803 [TBL] [Abstract][Full Text] [Related]
34. Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology. Hemmi T; Ainai A; Hashiguchi T; Tobiume M; Kanno T; Iwata-Yoshikawa N; Iida S; Sato Y; Miyamoto S; Ueno A; Sano K; Saito S; Shiwa-Sudo N; Nagata N; Tamura K; Suzuki R; Hasegawa H; Suzuki T Vaccine; 2022 Sep; 40(41):5892-5903. PubMed ID: 36064667 [TBL] [Abstract][Full Text] [Related]
36. An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response. Chen L; Zhang H; Li M; Wu B; Zhang Z; Gong R Front Immunol; 2022; 13():1005321. PubMed ID: 36466882 [TBL] [Abstract][Full Text] [Related]